RENOVORX INC (RNXT) Fundamental Analysis & Valuation

NASDAQ:RNXT • US75989R1077

0.808 USD
+0.01 (+1.62%)
At close: Mar 12, 2026
0.8278 USD
+0.02 (+2.45%)
After Hours: 3/12/2026, 8:09:08 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This RNXT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RNXT. RNXT was compared to 519 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RNXT as it has an excellent financial health rating, but there are worries on the profitability. RNXT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. RNXT Profitability Analysis

1.1 Basic Checks

  • In the past year RNXT has reported negative net income.
  • RNXT had a negative operating cash flow in the past year.
  • In the past 5 years RNXT always reported negative net income.
  • In the past 5 years RNXT always reported negative operating cash flow.
RNXT Yearly Net Income VS EBIT VS OCF VS FCFRNXT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -99.10%, RNXT is doing worse than 74.57% of the companies in the same industry.
  • RNXT's Return On Equity of -137.47% is on the low side compared to the rest of the industry. RNXT is outperformed by 61.46% of its industry peers.
Industry RankSector Rank
ROA -99.1%
ROE -137.47%
ROIC N/A
ROA(3y)-314.19%
ROA(5y)-236.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RNXT Yearly ROA, ROE, ROICRNXT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • Looking at the Gross Margin, with a value of 67.78%, RNXT belongs to the top of the industry, outperforming 80.15% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for RNXT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNXT Yearly Profit, Operating, Gross MarginsRNXT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RNXT Health Analysis

2.1 Basic Checks

  • RNXT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • RNXT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, RNXT has more shares outstanding
  • RNXT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RNXT Yearly Shares OutstandingRNXT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
RNXT Yearly Total Debt VS Total AssetsRNXT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • RNXT has an Altman-Z score of -4.08. This is a bad value and indicates that RNXT is not financially healthy and even has some risk of bankruptcy.
  • RNXT has a Altman-Z score (-4.08) which is in line with its industry peers.
  • RNXT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.08
ROIC/WACCN/A
WACC8.85%
RNXT Yearly LT Debt VS Equity VS FCFRNXT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M 15M

2.3 Liquidity

  • A Current Ratio of 5.83 indicates that RNXT has no problem at all paying its short term obligations.
  • RNXT's Current ratio of 5.83 is fine compared to the rest of the industry. RNXT outperforms 61.66% of its industry peers.
  • RNXT has a Quick Ratio of 5.68. This indicates that RNXT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 5.68, RNXT is in the better half of the industry, outperforming 61.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.83
Quick Ratio 5.68
RNXT Yearly Current Assets VS Current LiabilitesRNXT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. RNXT Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 36.21% over the past year.
EPS 1Y (TTM)36.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • RNXT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.17% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y19.04%
EPS Next 2Y16.45%
EPS Next 3Y23.44%
EPS Next 5Y35.17%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RNXT Yearly Revenue VS EstimatesRNXT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
RNXT Yearly EPS VS EstimatesRNXT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

1

4. RNXT Valuation Analysis

4.1 Price/Earnings Ratio

  • RNXT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNXT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNXT Price Earnings VS Forward Price EarningsRNXT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNXT Per share dataRNXT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 -0.3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RNXT's earnings are expected to grow with 23.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.45%
EPS Next 3Y23.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RNXT Dividend Analysis

5.1 Amount

  • No dividends for RNXT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RNXT Fundamentals: All Metrics, Ratios and Statistics

RENOVORX INC

NASDAQ:RNXT (3/12/2026, 8:09:08 PM)

After market: 0.8278 +0.02 (+2.45%)

0.808

+0.01 (+1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)04-01
Inst Owners11.92%
Inst Owner Change-18.55%
Ins Owners4.64%
Ins Owner Change3.9%
Market Cap29.61M
Revenue(TTM)928.00K
Net Income(TTM)-11.11M
Analysts82
Price Target6.89 (752.72%)
Short Float %1.35%
Short Ratio1.78
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.84%
Min EPS beat(2)1.96%
Max EPS beat(2)7.73%
EPS beat(4)3
Avg EPS beat(4)-1.05%
Min EPS beat(4)-15.86%
Max EPS beat(4)7.73%
EPS beat(8)6
Avg EPS beat(8)8.57%
EPS beat(12)8
Avg EPS beat(12)6.38%
EPS beat(16)11
Avg EPS beat(16)4.26%
Revenue beat(2)1
Avg Revenue beat(2)-5.08%
Min Revenue beat(2)-35.66%
Max Revenue beat(2)25.5%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.66%
PT rev (3m)20%
EPS NQ rev (1m)2.44%
EPS NQ rev (3m)3.03%
EPS NY rev (1m)0.78%
EPS NY rev (3m)0.78%
Revenue NQ rev (1m)-6.17%
Revenue NQ rev (3m)-6.17%
Revenue NY rev (1m)6.91%
Revenue NY rev (3m)6.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.91
P/FCF N/A
P/OCF N/A
P/B 3.67
P/tB 3.67
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0.03
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -99.1%
ROE -137.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.78%
FCFM N/A
ROA(3y)-314.19%
ROA(5y)-236.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.83
Quick Ratio 5.68
Altman-Z -4.08
F-Score5
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y19.04%
EPS Next 2Y16.45%
EPS Next 3Y23.44%
EPS Next 5Y35.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.98%
OCF growth 3YN/A
OCF growth 5YN/A

RENOVORX INC / RNXT FAQ

What is the ChartMill fundamental rating of RENOVORX INC (RNXT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RNXT.


What is the valuation status for RNXT stock?

ChartMill assigns a valuation rating of 1 / 10 to RENOVORX INC (RNXT). This can be considered as Overvalued.


What is the profitability of RNXT stock?

RENOVORX INC (RNXT) has a profitability rating of 1 / 10.


What is the earnings growth outlook for RENOVORX INC?

The Earnings per Share (EPS) of RENOVORX INC (RNXT) is expected to grow by 19.04% in the next year.